Global Health Limited · NSE:MEDANTA
Global Health — Q2 FY2026 Earnings Presentation
34 slides from Global Health's earnings presentation, Nov 7, 2025
Slide 1: Cover letter to stock exchanges
November 07 , 2025 Ref:- GHL/2025-26/EXCH/77 The General Manager The Manager Dept. of Corporate Services Listing Department BSE Limited, National Stock Exchange of India Limited P J Towers, Dalal Street, Exchange Plaza, C-1, Block G, Mumbai - 400 001 Bandra Kurla Complex, Bandra (E), Mumbai - 400 05
Slide 2: Investor Presentation Q2 and H1 FY2026
GLOBAL HEALTH LIMITED Dedicated to Life Investor Presentation Q2 and H1 FY2026 5 7th November, 2025 1
Slide 3: Disclaimer
Disclaimer This presentation, apart from historical information, contains some "forward-looking statements" including those describing the Company’s strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties
Slide 4: Contents
Contents 01 Q2 and H1 FY2026 Performance Update 02 Project Update and Capex Plan 03 Medanta’s Journey, Purpose and Model of Healthcare 04 Annexures 3
Slide 5: Q2 and H1 FY2026 Performance Update
01 Q2 and H1 FY2026 Performance Update 4
Slide 6: Q2 FY2026 performance summary
Q2 FY2026 performance summary Revenue Growth of 15% y-o-y and EBITDA growth (ex Noida) of 14% y-o-y INR 11,189 million INR 2,804 million INR 2,607 million INR 1,584 million Total Income1 incl. Noida ex Noida2 EBITDA3 Margin: 25.2% EBITDA3 Margin: 23.3% Margin: 14.2% PAT Q2 FY25 Q2 FY25 Q2 FY25 Q2 FY
Slide 7: Q2 FY2026 performance summary
Q2 FY2026 performance summary Revenue growth of 15% y-o-y, primarily led by increase in patient volumes and realization Consolidated Total Income of INR 11,189 million, compared to INR 9,748 million in Q2 FY25; reflecting a growth of 14.8 % y-o-y EBITDA1 (ex-Noida3) grew 13.7 % y-o-y to INR 2,804 wi
Slide 8: Medanta Noida: Launched on 1st September, 2025
Medanta Noida: Launched on 1st September, 2025 Commenced phase I of 300 beds; 226 beds and 5 OTs operational as at the end of Q2 FY26 Medanta Noida Overview 550+ 226 Planned beds capacity Operational beds 80+ 150+ ICU Beds Experienced Doctors 60+ 500+ Senior clinicians Nurses and paramedics 950+ 20+
Slide 9: Latest advanced technology deployed at Noida
Latest advanced technology deployed at Noida Providing the latest tools to enable our doctors to deliver the greatest care O-arm O2 Surgical Da Vinci Xi Robotic ARTIS icono BiPlane Imaging System System CATH Lab SOMATOM Pro. ARTIS icono Ceiling MAGNETOM Lumina Pulse with Abbott EP 3T MRI Dual Source
Slide 10: Q2 FY2026 Business Update
Q2 FY2026 Business Update Strengthening the core and building strong pipeline for growth New Medical Equipment Deployed in Q2 FY26 Capacity Expansion (ex Noida) Patna: Total of 37 beds added in Q2 FY26. Total 57 bed addition in H1 FY26 Noida: Commenced phase 1 of 300 beds in Sep 2025. Operationa
Slide 11: Key operating metrics: Revenue and profitability
Key operating metrics: Revenue and profitability Revenue growth of 14% y-o-y and 6% on a sequential basis and EBITDA up by 14% (ex Noida) Total Income (INR million) EBITDA1 (INR million and margin %) +14.4% +14.8% +13.7% +5.7% 10,513 11,151 11,189 9,748 +6.1% 2,804 2,607 2,465 2,553 +9.8% Q2 FY25 Q1
Slide 12: Key operating metrics: Volumes, occupancies, ALOS
Key operating metrics: Volumes, occupancies, ALOS Occupied bed days grew by 8%, driven by in-patient volume growth of 13% y-o-y, occupancy at 64% in Q2 FY26 Average census and occupied beds ALOS (days) +7.6% -4.4% 3.20 3.03 3.06 +8.7% 2,446 2,487 2,658 1,573 1,571 1,693 Q2 FY25 Q1 FY26 Q2 FY26 Q2 FY
Slide 13: Key operating metrics: ARPOB and revenue mix
Key operating metrics: ARPOB and revenue mix ARPOB growth driven change in specialty mix; cancer contribution is increasing ARPOB* (INR) IPD Revenue mix by payor category +5.5% 66,584 65,570 62,141 57% 55% 56% 25% 27% 25% 4% 4% 4% 10% 4% 11% 3% 12% 3% Q2 FY25 Q1 FY26 Q2 FY26 Q2 FY25 Q1 FY26 Q2 FY26
Slide 14: Diverse revenue mix
Diverse revenue1 mix Significant contribution from complex specialties. Cancer contribution is increasing Heart 21.5% 21.0% 20.7% Cancer 13.7% 14.2% 14.5% Digestive 11.5% 11.3% 12.1% Neuro 11.5% 11.3% 11.0% Kidney & Urology 7.7% 7.6% 7.4% Internal Medicine 6.9% 5.8% 5.8% Ortho 4.4% 5.7% 5.2% 3.1% 3.
Slide 15: Growth seen in both mature and new hospitals
Growth seen in both mature and new hospitals Developing hospitals delivered robust revenue and EBITDA y-o-y growth Matured hospitals - Over 6 years Developing hospitals - Less than 6 years Total Income (INR million) EBITDA (INR million and margin %) Total Income (INR million) EBITDA (INR million and
Slide 16: H1 FY2026 performance summary
H1 FY2026 performance summary Well capitalized balance sheet and strong EBITDA to cash flow conversion Key Highlights INR million FY2022 FY2023 FY2024 FY2025 H1 FY2026 Gross Debt 8,379 8,422 4,193 3,279 5,267 • Gross Debt increased by INR 1,988 million Cash and Cash Equivalents 5,222 13,114 11,913 1
Slide 17: Project Update and Capex Plan
02 Project Update and Capex Plan 16
Slide 18: Guwahati project update: Bhoomi Poojan ceremony
Guwahati project update: Bhoomi Poojan ceremony held on 31st October, 2025 Land Parcel Offered: Acquired 3.5-acre land parcel with a cost of ~Rs. 600 million Strategic Location: Newly offered land is situated along the National Highway 27 Enhanced Accessibility: Prime location ensures easier a
Slide 19: Medanta Mumbai to now become a ~750 bed hospital
Medanta Mumbai to now became a ~750 bed hospital Super specialty hospital in Oshiwara, Mumbai The Company has bought 8,859 sq. meters of land in Oshiwara from MHADA for an amount of Rs. 125.11 crores in a public auction Final plot area is now 9,287.54 sqm after final measurement and company has
Slide 20: On-going expansion projects
On-going expansion projects Planned bed capacity addition; well positioned to drive near term growth Number of installed beds ~ 2,300 bed addition +56.3% 400 647 bed addition ~219 bed addition 393 bed addition 750 +18.8% 400 +7.8% +12.9% 250 750 74 100 100 23 2,823 226 100 6,382 49 58 112 57 110 3,0
Slide 21: Capex plan next 5 years
Capex plan next 5 years Total capex of over ~INR 41,200 million planned for next 5 years 2,421 3,000 5,032 5,851 41,224 13,850 35,803 3,645 4,500 2,164 761 Maintenance Lucknow, Noida South Mumbai Pitampura, Guwahati Medical Guest Total Capex Capex for 3 Patna and Delhi- DLF Delhi School House Years
Slide 22: Medanta's Journey, Purpose and Model of Healthcare
Medanta’s Journey, Purpose and 03 Model of Healthcare 21
Slide 23: Medanta was founded to bring a new type of healthcare to India
Medanta was founded to bring a new type of healthcare to India… … the human side of healthcare Healthcare is never only about science. It is also about the art of medicine – the human connection, putting the patient first, collaboration, the personal acts of empathy and the values that guide our dec
Slide 24: Growth from a single flagship hospital in Gurgaon
Growth from a single flagship hospital in Gurgaon… …to a network of 6 high quality hospitals across north India FY2026 MEDANTA 2025 HOSPITAL MEDANTA NOIDA 2021 HOSPITAL 550 Beds JAI PRABHA Ranchi** Commence operations 2019 MEDANTA SPECIALTY in September 2025 110 Beds MEDANTA HOSPITAL with 226 beds C
Slide 25: Grown to ~3,435 beds across 6 cities
From our flagship Medicity campus in Gurgaon, we have grown to ~3,435 beds across 6 cities Largest private hospital beds in operation under one roof in Delhi (NCR), Uttar Pradesh and Bihar Gurgaon LUCKNOW PATNA 1,440 beds; 316 ICU beds 757 beds; 202 ICU beds (950 planned) 527 beds; 147 ICU beds (650
Slide 26: One of the largest private hospital chains in North and East India
One of the largest private hospital chains in North and East India Serving over 400 million people in the States with Medanta facilities Gurugram; Largest single location private hospital in with operational Delhi; ~1,150 bed addition bed capacity of 1,440 Our Network planned with 750 beds in Pitamp
Slide 27: Our Mission and Values
Our Mission and Values Embracing a new era and redefining our purpose Core Values Patient centric care: Foster a culture where every one of us is MISSION committed to care for patients and their caregivers Our mission is to deliver Leadership and quality: Commit to delivering excellence in world cla
Slide 28: The Medanta Model of Healthcare
The Medanta Model of Healthcare Delivering the highest quality of medicine with care and compassion Exceptional clinical talent What it means for patients and caregivers? • Super specialized doctors provide the highest quality of care through a team based integrated approach Trust based compassionat
Slide 29: Medanta is well placed to deliver sustainable growth
Medanta is well placed to deliver sustainable growth… …while maintaining its core values of patient centric care and clinical leadership and quality CONTINUITY OF CARE TECHNOLOGY Extend clinical THOUGHT ADVANCEMENT services outside LEADERSHIP Use technology to hospital and ENHANCE Build on our impro
Slide 30: Annexures
04 Annexures 29
Slide 31: Annexure: Profit and Loss Statement
Annexure: Profit and Loss Statement Half Year Quarter Y-o-Y Y-o-Y INR million H1 FY25 H1 FY26 Q2 FY25 Q1 FY26 Q2 FY26 Growth % Growth % Revenue from operations 18,176 21,301 17.2% 9,566 10,308 10,992 14.9% Other income 401 402 0.1% 182 205 197 8.3% Total income 18,578 21,702 16.8% 9,748 10,513 11,18
Slide 32: Annexure: Operational Parameters
Annexure: Operational Parameters Year End Quarter Y-o-Y Growth Y-o-Y Growth Q-o-Q Growth Key metrics H1 FY25 H1 FY26 Q2 FY25 Q1 FY26 Q2 FY26 % % % Total Beds 3,008 3,435 14.2% 3,008 3,062 3,435 14.2% 12.2% Census Beds 2,400 2,573 7.2% 2,446 2,487 2,658 8.7% 6.9% Occupied Bed Days 2,70,636 2,98,627 1
Slide 33: Annexure: Abbreviations and Definitions
Annexure: Abbreviations and Definitions Abbreviations INR : Indian Rupee NABH : National Accreditation Board for Hospitals & Healthcare Providers NABL : National Accreditation Board for Testing and Calibration Laboratories JCI : Joint Commission International OPD : Out-Patient Department
Slide 34: Contact us
Contact us About Medanta Contact Details Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and Ravi Gothwal – cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest Head of Investor Relations civilian awards in India, a